Adial Pharmaceuticals, Inc. (ADIL) insider trading.
In Q3 2026, insiders at Adial Pharmaceuticals, Inc. reported 5 non-derivative transactions on 4 Forms 3, 4 and 5: 5 open-market purchases worth $106K and 0 sales.
- Transactions
- 5
- Purchases (P)
- 5
- Sales (S)
- 0
- Net shares, P minus S
- 39,986
- Insiders
- 1
- Last filed
- 2026-07-16
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Coastlands Capital LP | TenPercentOwner | 5 | 5 | 0 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-07-16 | Coastlands Capital LP | P (A) | 1,233 | $2.75 | 388,308 | Form 4 |
| 2026-07-14 | Coastlands Capital LP | P (A) | 2,000 | $2.65 | 387,075 | Form 4 |
| 2026-07-10 | Coastlands Capital LP | P (A) | 1,700 | $2.7 | 385,075 | Form 4 |
| 2026-07-09 | Coastlands Capital LP | P (A) | 10,053 | $2.79 | 383,375 | Form 4 |
| 2026-06-29 | Coastlands Capital LP | P (A) | 25,000 | $2.6 | 373,322 | Form 4 |
Transaction codes in this quarter
Get ADIL insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1513525&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · ADIL company page · Adial Pharmaceuticals, Inc. on SEC.gov
Questions
Are insiders buying or selling Adial Pharmaceuticals, Inc. (ADIL)?
In Q3 2026, insiders at Adial Pharmaceuticals, Inc. reported 5 non-derivative transactions on 4 Forms 3, 4 and 5: 5 open-market purchases worth $106K and 0 sales. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Adial Pharmaceuticals, Inc. insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/adil.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.